Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases
Abstract Background The purpose of this study was to determine the risk factors for and incidence as well as prognostic impact of pathologic fracture (PF) and metastatic spinal cord compression (MSCC) in patients with bone metastases (BM) from prostate cancer. Methods Retrospective cohort study incl...
Main Authors: | , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BioMed Central Ltd.
2010
|
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2490/10/23 |
id |
ftbiomed:oai:biomedcentral.com:1471-2490-10-23 |
---|---|
record_format |
openpolar |
spelling |
ftbiomed:oai:biomedcentral.com:1471-2490-10-23 2023-05-15T17:24:40+02:00 Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases Nieder, Carsten Haukland, Ellinor Pawinski, Adam Dalhaug, Astrid 2010-12-22 http://www.biomedcentral.com/1471-2490/10/23 en eng BioMed Central Ltd. http://www.biomedcentral.com/1471-2490/10/23 Copyright 2010 Nieder et al; licensee BioMed Central Ltd. Research article 2010 ftbiomed 2011-01-16T00:34:24Z Abstract Background The purpose of this study was to determine the risk factors for and incidence as well as prognostic impact of pathologic fracture (PF) and metastatic spinal cord compression (MSCC) in patients with bone metastases (BM) from prostate cancer. Methods Retrospective cohort study including 61 consecutive patients seen at Nordland hospital's department of oncology between 2007 and 2009. The initial diagnosis of BM might have been made earlier. Twenty-nine patients (48%) received taxotere and 72% zoledronic acid after diagnosis of BM. Results Median actuarial survival after diagnosis of BM was 23 months. Six patients (10%) were alive at 5 years. Bone pain at baseline was present in 49% of patients. Eighty-nine percent required external beam radiotherapy and/or radioisotopes after diagnosis of BM. Seventeen patients (28%) developed at least one major skeletal complication, i.e. MSCC or PF (4 of them developed more than one). The actuarial risk was 44% at 4 and 5 years. Most events developed before treatment with zoledronic acid and/or taxotere. Median survival from diagnosis of either MSCC or PF was 11 months (5 months from MSCC). We did not identify statistically significant risk factors for development of major skeletal complications. Serum alkaline phosphatase above median value and age less than or equal to 70 years were the only risk factors approaching significance. Conclusions We found high rates of major skeletal complications in this unselected contemporary group of patients. Identification of risk factors might guide the development of early interventions aiming at prevention of MSCC and PF. Article in Journal/Newspaper Nordland Nordland Nordland BioMed Central |
institution |
Open Polar |
collection |
BioMed Central |
op_collection_id |
ftbiomed |
language |
English |
description |
Abstract Background The purpose of this study was to determine the risk factors for and incidence as well as prognostic impact of pathologic fracture (PF) and metastatic spinal cord compression (MSCC) in patients with bone metastases (BM) from prostate cancer. Methods Retrospective cohort study including 61 consecutive patients seen at Nordland hospital's department of oncology between 2007 and 2009. The initial diagnosis of BM might have been made earlier. Twenty-nine patients (48%) received taxotere and 72% zoledronic acid after diagnosis of BM. Results Median actuarial survival after diagnosis of BM was 23 months. Six patients (10%) were alive at 5 years. Bone pain at baseline was present in 49% of patients. Eighty-nine percent required external beam radiotherapy and/or radioisotopes after diagnosis of BM. Seventeen patients (28%) developed at least one major skeletal complication, i.e. MSCC or PF (4 of them developed more than one). The actuarial risk was 44% at 4 and 5 years. Most events developed before treatment with zoledronic acid and/or taxotere. Median survival from diagnosis of either MSCC or PF was 11 months (5 months from MSCC). We did not identify statistically significant risk factors for development of major skeletal complications. Serum alkaline phosphatase above median value and age less than or equal to 70 years were the only risk factors approaching significance. Conclusions We found high rates of major skeletal complications in this unselected contemporary group of patients. Identification of risk factors might guide the development of early interventions aiming at prevention of MSCC and PF. |
format |
Article in Journal/Newspaper |
author |
Nieder, Carsten Haukland, Ellinor Pawinski, Adam Dalhaug, Astrid |
spellingShingle |
Nieder, Carsten Haukland, Ellinor Pawinski, Adam Dalhaug, Astrid Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
author_facet |
Nieder, Carsten Haukland, Ellinor Pawinski, Adam Dalhaug, Astrid |
author_sort |
Nieder, Carsten |
title |
Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
title_short |
Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
title_full |
Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
title_fullStr |
Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
title_full_unstemmed |
Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
title_sort |
pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases |
publisher |
BioMed Central Ltd. |
publishDate |
2010 |
url |
http://www.biomedcentral.com/1471-2490/10/23 |
genre |
Nordland Nordland Nordland |
genre_facet |
Nordland Nordland Nordland |
op_relation |
http://www.biomedcentral.com/1471-2490/10/23 |
op_rights |
Copyright 2010 Nieder et al; licensee BioMed Central Ltd. |
_version_ |
1766115786377658368 |